These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30907011)

  • 1. TAK1 is a druggable kinase for diffuse large B-cell lymphoma.
    Wu Y; Yang R; Ming Y; Xu Y; Chen H; Yao M; Chen X; Mao R; Fan Y
    Cell Biochem Funct; 2019 Apr; 37(3):153-160. PubMed ID: 30907011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
    He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
    Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
    Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
    Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
    Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
    Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.
    Paul J; Soujon M; Wengner AM; Zitzmann-Kolbe S; Sturz A; Haike K; Keng Magdalene KH; Tan SH; Lange M; Tan SY; Mumberg D; Lim ST; Ziegelbauer K; Liu N
    Cancer Cell; 2017 Jan; 31(1):64-78. PubMed ID: 28073005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.
    Zhang XT; Hu XB; Wang HL; Kan WJ; Xu L; Wang ZJ; Xiang YQ; Wu WB; Feng B; Li JN; Gao AH; Dong TC; Xia CM; Zhou YB; Li J
    Acta Pharmacol Sin; 2021 May; 42(5):814-823. PubMed ID: 32855532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
    Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
    Ceribelli M; Kelly PN; Shaffer AL; Wright GW; Xiao W; Yang Y; Mathews Griner LA; Guha R; Shinn P; Keller JM; Liu D; Patel PR; Ferrer M; Joshi S; Nerle S; Sandy P; Normant E; Thomas CJ; Staudt LM
    Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11365-70. PubMed ID: 25049379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas.
    Islam S; Qi W; Morales C; Cooke L; Spier C; Weterings E; Mahadevan D
    Mol Cancer Ther; 2017 Oct; 16(10):2083-2093. PubMed ID: 28615297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
    Kuo HP; Ezell SA; Schweighofer KJ; Cheung LWK; Hsieh S; Apatira M; Sirisawad M; Eckert K; Hsu SJ; Chen CT; Beaupre DM; Versele M; Chang BY
    Mol Cancer Ther; 2017 Jul; 16(7):1246-1256. PubMed ID: 28428442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.
    Mondello P; Brea EJ; De Stanchina E; Toska E; Chang AY; Fennell M; Seshan V; Garippa R; Scheinberg DA; Baselga J; Wendel HG; Younes A
    JCI Insight; 2017 Mar; 2(6):e90196. PubMed ID: 28352655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
    Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
    J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.
    Luo Q; Pan W; Zhou S; Wang G; Yi H; Zhang L; Yan X; Yuan L; Liu Z; Wang J; Chen H; Qiu M; Yang D; Sun J
    Oncol Res; 2020 Sep; 28(4):331-344. PubMed ID: 32093809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
    Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
    Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
    Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
    Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
    Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
    Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.
    Li C; Thompson MA; Tamayo AT; Zuo Z; Lee J; Vega F; Ford RJ; Pham LV
    Oncotarget; 2012 Mar; 3(3):314-26. PubMed ID: 22447839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells.
    Jin F; He L; Chen Y; Tian W; Liu L; Ge L; Qian W; Xia L; Yang M
    Braz J Med Biol Res; 2024; 57():e13278. PubMed ID: 39383379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.